KIOVIG (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
KIOVIG
Date registered
Evaluation commenced
Decision date
Approval time
229 (255 working days)
Active ingredients
normal immunoglobulin
Registration type
EOI
Indication
KIOVIG (solution for injection) administered intravenously is now also indicated for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in adults.